Alliance Design and Development Group

Alliance Design and Development Group has been granted 10 US utility patents between 2017 and 2023, placing Alliance Design and Development Group at rank #25,768 across all assignees tracked by PlainPatent. This portfolio spans 10 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.6 claims per patent with primary concentration in A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). As a US Corporation, Alliance Design and Development Group is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 30.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 2 grants, compared with 8 in the 2015–2019 window — a -75% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Alliance Design and Development Group's 16.6 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 10 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Alliance Design and Development Group against peers pursuing similar technology classes.